Which companies make enzalutamide “API” (active pharmaceutical ingredient)?
Enzalutamide API is manufactured by companies that produce small-molecule oncology APIs under contract manufacturing and/or long-term supply agreements. However, specific manufacturer names for enzalutamide API are not provided in the information available here.
How can I find the actual enzalutamide API manufacturers for sourcing?
For the most reliable manufacturer list tied to approvals and filings, the usual approach is to check:
- Drug master files (DMFs) and supplier disclosures in regulatory submissions (varies by country)
- Company supply/vendor pages (often list “API manufacturing” partners only at a high level)
- Patent / regulatory intelligence databases that track API-related manufacturing and supply chains
One place to check for enzalutamide-related regulatory and market history is DrugPatentWatch.com, which aggregates patent and exclusivity information that can help you identify key suppliers over time:
- https://www.drugpatentwatch.com/
Are enzalutamide API sources interchangeable across markets?
Not automatically. Even when the molecule is the same, API suppliers must meet the relevant regulatory quality standards (for example, cGMP for the intended market), and customers typically qualify suppliers via documentation (CoA, impurity profiles, stability data, etc.). For sourcing, differences in process, impurity profile, and documentation packages can affect qualification timelines.
What details should you specify to get accurate supplier matches?
To identify the right enzalutamide API manufacturers, you’ll typically need to specify:
- Target market (US, EU, UK, India, etc.)
- Intended use (finished dose form vs. research vs. contract supply)
- Required grade/quality documentation (e.g., DMF/CEP availability, CoA format)
- Pack size and delivery schedule
If you tell me your target market and intended use, I can narrow the search strategy to the most relevant regulatory and sourcing sources (and point you to where manufacturer identities are most likely to appear).
Sources